

ASX ANNOUNCEMENT


12 February 2020

APPOINTMENT OF DIRECTOR

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”) would like to advise that Dr Thomas Duthy has been appointed as a Non-Executive Director of the Company, effective Tuesday 11th February, 2020.

Tom has over 15 years of direct financial market and medical device industry experience. Tom is the Founder and CEO of Nemean Group Pty Ltd, a boutique corporate advisory, investor relations and equity research group based in Adelaide, Australia with a focus on micro to small cap ASX-listed companies. Prior to establishing Nemean Group, he was Global Head of Investor Relations and Corporate Development at Sirtex Medical Limited (ASX:SRX), which was sold for \$1.9 billion in late 2018 and to date is the largest medical device transaction in Australian corporate history. Additionally, he spent 10 years as a leading sector analyst specialising in Healthcare and Biotechnology companies.

Mr Nicholas Smedley, Executive Chairman of Respiri said, “On behalf of the Board of Respiri, I would like to welcome Tom to the Company. Tom brings significant industry and corporate expertise, which is a highly complementary set of skills as we progressively execute on our transformation plans for Respiri to an e-health SaaS Company in respiratory disease management throughout 2020 and beyond.”



Alastair Beard
Company Secretary
alastair@respiri.co

---End---

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri's current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.